Aura Biosciences, Inc. (AURA) 10-Year Financial Performance & Capital Metrics

AURA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutAura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $0
EBITDA -$95M -13.4%
Net Income -$87M -13.8%
EPS (Diluted) -1.75 +9.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -46.01% -26.9%
ROIC -41.99% +1.5%
Debt/Equity 0.12 +42.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Shares diluted 25.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-27.94%

EPS CAGR

10Y-

5Y-

3Y-

TTM-12.14%

ROCE

10Y Avg-54.05%

5Y Avg-49.24%

3Y Avg-39.02%

Latest-46.85%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	509K	0	0	0	1.29M	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-509K	0	0	0	-1.29M	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	1%	-	-	-	1%
Operating Expenses+	23.63M	22.21M	35.25M	60.3M	83.7M	96.12M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	4.52M	4.16M	10.09M	18.06M	19.76M	22.81M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	19.11M	18.04M	25.16M	42.24M	63.94M	73.3M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-24.14M	-22.21M	-35.25M	-60.3M	-84.99M	-96.12M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	0.08%	-0.59%	-0.71%	-0.41%	-0.13%
EBITDA+	-23.63M	-21.38M	-34.42M	-59.12M	-83.7M	-94.89M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	0.1%	-0.61%	-0.72%	-0.42%	-0.13%
D&A (Non-Cash Add-back)	509K	831K	831K	1.18M	1.29M	1.22M
EBIT	-24.2M	-22.21M	-35.25M	-60.3M	-84.99M	-96.12M
Net Interest Income+	-5K	-3K	0	1.86M	8.59M	9.43M
Interest Income	5	3	13K	1.86M	8.59M	9.43M
Interest Expense	5K	3K	13K	0	0	0
Other Income/Expense	-60K	0	-1K	1.53M	8.72M	9.31M
Pretax Income+	-24.2M	-22.21M	-35.25M	-58.76M	-76.27M	-86.81M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	137K	112K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-24.2M	-22.21M	-35.25M	-58.76M	-76.41M	-86.92M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	0.08%	-0.59%	-0.67%	-0.3%	-0.14%
Net Income (Continuing)	-24.2M	-22.21M	-35.25M	-58.76M	-76.41M	-86.92M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-1.03	-1.58	-1.96	-1.93	-1.75
EPS Growth %	-	-	-0.53%	-0.24%	0.02%	0.09%
EPS (Basic)	-0.01	-1.03	-1.58	-1.96	-1.93	-1.75
Diluted Shares Outstanding	2.92B	29.22M	29.21M	29.94M	39.62M	49.65M
Basic Shares Outstanding	2.92B	29.22M	29.21M	29.94M	39.62M	49.65M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	33.35M	18.45M	153.7M	196.7M	231.79M	160.62M
Cash & Short-Term Investments	32.47M	17.39M	149.06M	188.81M	226.15M	151.09M
Cash Only	32.47M	17.39M	149.06M	121.58M	41.06M	31.69M
Short-Term Investments	0	0	0	67.23M	185.09M	119.4M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	56K	35K	89K	5.72M	3.83M	1.83M
Total Non-Current Assets+	3.71M	3.65M	6.33M	27.23M	23.28M	21.88M
Property, Plant & Equipment	3.63M	3.57M	6.2M	26.04M	22M	20.59M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	75K	0	0	768K	0	0
Other Non-Current Assets	0	75K	125K	423K	1.28M	1.29M
Total Assets+	37.05M	22.1M	160.03M	223.94M	255.07M	182.5M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.4%	6.24%	0.4%	0.14%	-0.28%
Total Current Liabilities+	6.15M	2.66M	7.36M	10.46M	12.36M	14.91M
Accounts Payable	2.33M	611K	2.4M	2.92M	1.79M	2.3M
Days Payables Outstanding	1.67K	-	-	-	503.67	-
Short-Term Debt	0	15K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	2.52M	1.28M	2.65M	3.03M	935K	618K
Current Ratio	5.42x	6.94x	20.90x	18.81x	18.76x	10.77x
Quick Ratio	5.42x	6.94x	20.90x	18.81x	18.76x	10.77x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	144K	80K	360K	17.89M	16.87M	15.62M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	49K	0	360K	17.89M	16.87M	15.62M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	95K	80K	0	0	0	0
Total Liabilities	6.29M	2.74M	7.71M	28.35M	29.23M	30.53M
Total Debt+	49K	15K	975K	20.86M	19.56M	18.77M
Net Debt	-32.42M	-17.38M	-148.09M	-100.72M	-21.51M	-12.92M
Debt / Equity	0.00x	0.00x	0.01x	0.11x	0.09x	0.12x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-4828.00x	-7402.00x	-2711.54x	-	-	-
Total Equity+	30.76M	19.36M	152.31M	195.58M	225.85M	151.97M
Equity Growth %	-	-0.37%	6.87%	0.28%	0.15%	-0.33%
Book Value per Share	0.01	0.66	5.21	6.53	5.70	3.06
Total Shareholders' Equity	30.76M	19.36M	152.31M	195.58M	225.85M	151.97M
Common Stock	0	0	0	0	0	0
Retained Earnings	-94.68M	-116.89M	-152.14M	-210.9M	-287.31M	-374.23M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	-72K	539K	263K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.67M	-24.32M	-32.41M	-54.6M	-63.85M	-79.81M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.18%	-0.33%	-0.68%	-0.17%	-0.25%
Net Income	-24.2M	-22.21M	-35.25M	-58.76M	-76.41M	-86.92M
Depreciation & Amortization	509K	831K	831K	1.18M	1.29M	1.22M
Stock-Based Compensation	507K	736K	2.31M	6.41M	8.77M	11.72M
Deferred Taxes	0	0	14K	0	0	0
Other Non-Cash Items	54K	-3K	4K	-325K	-1.95M	-3.19M
Working Capital Changes	2.46M	-3.68M	-315K	-3.1M	4.44M	-2.64M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	1.04M	-1.72M	1.05M	340K	-1.04M	482K
Cash from Investing+	-2.22M	-771K	-2.13M	-67.87M	-113.96M	68.82M
Capital Expenditures	-2.22M	-771K	-2.13M	-1.09M	-709K	-1.25M
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	-66.78K	0	0
Cash from Financing+	39.73M	10.04M	166.26M	95.63M	97.29M	1.59M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	57K	163K	334K	430K	1.5M	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-22.89M	-25.09M	-34.53M	-55.7M	-64.56M	-81.06M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.1%	-0.38%	-0.61%	-0.16%	-0.26%
FCF per Share	-0.01	-0.86	-1.18	-1.86	-1.63	-1.63
FCF Conversion (FCF/Net Income)	0.85x	1.10x	0.92x	0.93x	0.84x	0.92x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-78.67%	-88.6%	-41.07%	-33.78%	-36.26%	-46.01%
Return on Invested Capital (ROIC)	-	-10124.32%	-851.18%	-91.28%	-42.61%	-41.99%
Debt / Equity	0.00x	0.00x	0.01x	0.11x	0.09x	0.12x
Interest Coverage	-4828.00x	-7402.00x	-2711.54x	-	-	-
FCF Conversion	0.85x	1.10x	0.92x	0.93x	0.84x	0.92x

Frequently Asked Questions

Growth & Financials

Aura Biosciences, Inc. (AURA) grew revenue by 0.0% over the past year. Growth has been modest.

Aura Biosciences, Inc. (AURA) reported a net loss of $106.5M for fiscal year 2024.

Dividend & Returns

Aura Biosciences, Inc. (AURA) has a return on equity (ROE) of -46.0%. Negative ROE indicates the company is unprofitable.

Aura Biosciences, Inc. (AURA) had negative free cash flow of $88.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener